Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor.

@article{Chida2005PharmacologicalPO,
  title={Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor.},
  author={Noboru Chida and Yoshimi Hirasawa and Takehiko Ohkawa and Yoshinori Ishii and Yuji Sudo and Kouichi Tamura and Seitaro Mutoh},
  journal={European journal of pharmacology},
  year={2005},
  volume={509 1},
  pages={71-6}
}
In this study, we examined effects of a newly synthesized chemical compound, FR260330, (2E)-3-(4-chlorophenyl)-N-[(1S)-2-oxo-2-{[2-oxo-2-(4-{[6-(trifluoromethyl)-4-pyrimidinyl]oxy}-1-piperidinyl)ethyl]amino}-1-(2-pyridinylmethyl)ethyl]acrylamide on nitric oxide (NO) production in rat splenocytes and human colon cancer cell line, DLD-1 cells. FR260330 inhibited NOx production dose dependently in both cells. In lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) treated murine macrophage… CONTINUE READING

Similar Papers

Loading similar papers…